O6-Benzylguanine Enhances the In Vitro Immunotoxic Activity of Temozolomide on Natural or Antigen-Dependent Immunity1

ESTER ALVINO, RITA PEPPONI, ELENA PAGANI, PEDRO MIGUEL LACLAL, CORRADO NUNZIATA, ENZO BONMASSAR, and STEFANIA D’ATRI

Institute of Experimental Medicine, National Council of Research, Rome, Italy (E.A.); and Istituto Dermopatico Dell’Immacolata, Rome, Italy (R.P., E.P., P.M.L., C.N., E.B., S.D.)

Accepted for publication August 20, 1999 This paper is available online at http://www.jpet.org

ABSTRACT

Temozolomide (TMZ) is a new cytotoxic triazene compound of clinical interest that is able to generate methyl adducts at the O6-guanine of DNA, which can be repaired by O6-alkylguanine-DNA alkyltransferase (OGAT). It was previously found that triazene compounds are highly immunosuppressive in mice. In the present study, we investigate whether TMZ could affect immune functions of human competent cells and whether methylation of O6-guanine could be involved in the immunosuppressive activity of the drug. Mononuclear cells (MNCs) obtained from peripheral blood of healthy donors were tested for OGAT activity and treated with TMZ alone or combined with the OGAT inhibitor O6-benzylguanine. Control or drug-treated MNCs were then assayed for natural killer activity and for the ability to proliferate and to generate cytotoxic effector cells in response to interleukin-2 or allogeneic MT-2 tumor cells. The results show that TMZ inhibited both proliferation and induction of lytic activity in response to interleukin-2 or allogeneic MT-2 cells. Moreover, an inverse correlation was found between the OGAT activity of MNCs and their sensitivity to TMZ. The involvement of O6-guanine methylation in the immunosuppressive effects of TMZ was further confirmed by the finding that O6-benzylguanine increased the activity of the drug. On the other hand, the natural killer activity of MNCs was only moderately affected by TMZ, and no relationship was observed between OGAT levels and sensitivity to the drug. These data suggest that in patients with tumors who are undergoing TMZ treatment, the drug may impair immune responses involving cell proliferation, depending on OGAT levels of MNCs, and that O6-benzylguanine may potentiate this activity.

1 This work was supported by the Italian Ministry of Health. A portion of the present work has been presented and is available in abstract form [Alvino E, Pepponi R, Pagani E, Ravagnan G, Bonmassar E and D’Attri S (1998) In vitro combined effect of temozolomide (TMZ) and O6-alkylguanine-DNA alkyltransferase (OGAT). Presented at the 22nd National Conference of Anticancer Research, October 21–25, 1998, Kallithea, Halkidiki, Greece].

Received for publication May 17, 1999.

ABBREVIATIONS: TMZ, temozolomide (8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one); BG, O6-benzylguanine; CM, complete medium; CTL, cytotoxic T lymphocytes; DTIC, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide; E, effector; O6-G, O6-guanine; 3H-TdR, [methyl-3H]thymidine deoxyriboside; IL, interleukin; LAK, lymphokine-activated killer; O6-MeG, O6-methylguanine; MNC, mononuclear cell; MTIC, 5-(3-methyl-1-triazeno)imidazole-4-carboxamide; NK, natural killer; OGAT, O6-alkylguanine-DNA alkyltransferase; T, target.
Depletion of OGAT, in tumors proficient for this protein, is considered to be a useful strategy to increase clinical responses to O\textsuperscript{6}-G-methylating agents (Dolan and Pegg, 1997). Indeed, depletion of OGAT activity by O\textsuperscript{6}-benzylguanine (BG), which acts as a potent substrate for the protein (Dolan et al., 1990), has been shown to increase tumor cell sensitivity to TMZ both in vitro (Baer et al., 1993; Tentori et al., 1995, 1997; Liu et al., 1996; Wedge et al., 1996a) and in vivo (Wedge and Newlands, 1996b; Wedge, 1997).

The mechanism by which the persistence of O\textsuperscript{6}-methylguanine (O\textsuperscript{6}-MeG) in DNA leads to cell cytotoxicity involves recognition of O\textsuperscript{6}-MeG-T and O\textsuperscript{6}-MeG-C mispairs, occurring during cell duplication, by the mismatch repair system (reviewed in Jiricny, 1996; Modrich, 1997). Thus, independent of their OGAT activity, tumor cell lines harboring mutations in the constituent proteins of the mismatch repair system are resistant to the cytotoxic effects of TMZ (Liu et al., 1996; D’Atri et al., 1998) and other O\textsuperscript{6}-G-methylating agents (Karan and Bignami, 1992; Kat et al., 1993; Carethers et al., 1996).

A number of studies are available suggesting that stimulation of the host’s immune system with immunomodulating agents or antitumor vaccines might be of benefit in the treatment of patients with cancer, particularly in the case of minimal residual disease (Ockert et al., 1999). Immunother-apy protocols based on DTIC plus interferon and/or interleukin (IL)-2 administration are already used in the treatment of metastatic melanoma (Cohen and Falkson, 1998). In these protocols, it is assumed that stimulation of the host’s immune function results in better clinical responses.

Previous studies performed in the murine model have shown that triazene compounds not only possess antitumor activity but also are immunosuppressive. Indeed, hemoral and cell-mediated immune responses are profoundly inhibited in mice exposed to DTIC (Giampietri and Bonmassar, 1978; Nardelli et al., 1984). Moreover, murine splenocytes treated in vitro with the drug show a marked impairment of antigen-dependent cell-mediated immunity and of prolliferative responses to mitogens (Giampietri and Bonmassar, 1978; Nardelli et al., 1984). On the other hand, the effects of triazene compounds on immune function of human competent cells have not been extensively investigated (Bonmassar et al., 1994), and no data are presently available on the immunosuppressive activity of TMZ.

As already occurring for DTIC, it is possible that TMZ could be used in association with immunomodulating agents in the treatment of melanoma. Therefore, studies have been performed to investigate whether the molecular mechanisms underlying the antitumor activity of TMZ may also be responsible for immunosuppressive effects. This was done to obtain useful information for a rational approach to cancer treatment based on TMZ associated with biological response modifiers. The present report illustrates the in vitro effects of TMZ, alone or in combination with BG, on natural or antigen-dependent cell-mediated immunity of human peripheral blood mononuclear cells (MNCs).

### Materials and Methods

#### Cell Lines and Culture Conditions

Erythroleukemia, K562, and Burkitt lymphoma, Daudi, cell lines were obtained from American Type Culture Collection (Rockville, MD). The human MT-2 cell line human T-cell leukemia virus type I-transformed cord blood T lymphocytes; Miyoshi et al., 1981) was kindly provided by Dr. B. Macchi (University of Tor Vergata, Rome, Italy). This cell line expresses class I and class II HLA antigens and B7 molecule and was used to elicit allogeneic antigen-dependent immune responses in human MNCs.

All cell lines were maintained in RPMI 1640 (Hyclone Europe, Cramlington, UK) supplemented with 10% heat-inactivated (56°C, 30 min) fetal calf serum (FCS, Hyclone), 2 mM l-glutamine, and antibiotics (Flow Laboratories, McLean, VA) and cultured at 37°C in 5% CO\textsubscript{2} humidified atmosphere.

#### Chemical and Biological Agents

TMZ was kindly provided by Schering-Plow Research Institute (Kenilworth, NJ). Because the drug readily decomposes in aqueous solution into MTIC (Stevens et al., 1987), solutions were always prepared fresh by dissolving the drug in RPMI 1640. The solutions were protected from light and used immediately after preparation. The OGAT inhibitor BG was synthesized and generously donated by Prof. L. Lassiani (Institute of Pharmacological Chemistry, University of Trieste, Italy). Mitomycin C (Kiowa Hakko Kogyo Co. Ltd., Tokyo, Japan) was diluted in water and stored at −80°C. Human recombinant IL-2 (kindly provided by Hoffman-La Roche, Basel, Switzerland) was diluted in RPMI 1640 medium and stored at −20°C.

#### Preparation of MNCs and In Vitro Treatment with TMZ and BG

MNCs were separated from the peripheral blood of healthy donors on a Ficoll-Hyapride gradient and washed twice in PBS. MNCs were then incubated (at 37°C for 1 h) in 50-ml tubes (Falcon; Becton and Dickinson Labware, Franklin Lakes, NJ; 2 × 10\textsuperscript{6} cells/ml; 10 ml/tube) in RPMI 1640 supplemented with 2% FCS, 2 mM l-glutamine, and antibiotics [hereafter referred to as complete medium (CM)] or in CM containing BG at the final concentration of 2 μM. Suspensions of control or BG-treated MNCs were then admixed with equal volumes of CM alone or CM containing TMZ to give final drug concentrations ranging between 62.5 and 500 μM and incubated at 37°C for 4 h. Because MNCs were not washed before the addition of TMZ, BG was always present during the 4-h treatment with the triazene compound. Thereafter, MNCs were washed in PBS and tested immediately for cytotoxic activity against K562 target cells [i.e., natural killer (NK) activity]. MNCs were also stimulated with IL-2 or allogeneic MT-2 tumor cells either in CM or in CM containing 2 μM BG. MNC responses to IL-2 or MT-2 cells were evaluated in terms of proliferation and generation of lymphokine-activated killer (LAK) cells or antigen-dependent cytotoxic T lymphocytes (CTL, see below).

To measure the effect of multiple exposures to TMZ, control or BG-treated MNCs (1 × 10\textsuperscript{6} cells/ml) were dispensed in 6-well (3 ml/well) or 96-well (0.2 ml/well) plates (Falcon) and treated daily with 50 μM TMZ for 5 days. The 5-day treatment of MNCs preexposed to BG was performed in the presence of BG 2 μM. Four hours after the last TMZ treatment, MNCs were tested for NK activity or stimulated with IL-2 or with allogeneic MT-2 tumor cells. Stimulation of MNCs treated with BG or TMZ plus BG was performed in the presence of BG 2 μM.

#### Evaluation of MNC Proliferative Responses

Control or drug-treated MNCs (1 × 10\textsuperscript{6} cells/ml in CM) were plated onto 96-well microtiter plates (0.2 ml/well) and stimulated with IL-2 (500 IU/ml) or with mitomycin-inactivated (80 μg/ml for 1 h) allogeneic MT-2 tumor cells (5 × 10\textsuperscript{3} cells/well) for 4 or 5 days, respectively. Stimulation of MNCs that had been preexposed to BG or TMZ plus BG was performed either in CM alone or in CM containing BG 2 μM. [methyl-\textsuperscript{3}H]Thymidine deoxyriboside (\textsuperscript{3}H-Tdr, Amersham International plc, Amersham, UK) was added to the cultures (5 μCi/ml) 18 h before the end of incubation, and radioactivity incorporation was determined by conventional liquid scintillation counting with a TRI-CARB 1900 counter (Packard Instrument Co., Meriden, CT).

#### In Vitro Generation of LAK Cells and CTL

To generate LAK cells, control or drug-treated MNCs (1 × 10\textsuperscript{6} cells/ml in CM) were dis-
pensed (3 ml/well) in 6-well plates and incubated with 500 IU/ml IL-2 at 37°C for 4 days. To generate allosensitized CTL, MNCs were plated as above and cocultured with mitomycin-inactivated MT-2 tumor cells (7.5 × 10⁵/well) at 37°C for 5 days. Stimulation of MNCs pretreated with BG or TMZ plus BG was performed either in the absence or the presence of BG 2 μM. At the end of incubation period, effector cells were recovered from the cultures and tested for cytotoxic activity against Daudi (LAK cells) or against MT-2 (CTL) target cells with the use of a conventional ³¹Cr-release assay (see below).

Cytotoxicity Assay. Aliquots of K562, Daudi, or MT-2 cells were centrifuged, resuspended in 0.1 ml of FCS, and incubated with 100 μCi of Na²⁹⁰CrO₄ (Amersham) at 37°C for 1 h. After incubation, the cells were extensively washed in RPMI 1640 medium, suspended in RPMI 1640 containing 10% FCS and 2 mM L-glutamine, and used in the cytotoxicity assay.

The cytotoxic activity of MNCs was determined using a ⁵¹Cr-release assay (Bonmassar et al., 1994). Effector cells, suspended in RPMI 1640 containing 10% FCS and glutamine, were plated (0.1 ml/well, in quadruplicate) onto U-bottomed 96-microtiter plates (Greiner GmbH, Frickenhausen, Germany) by making serial 2-fold dilutions, starting at a concentration of 2 × 10⁵ cells/ml. ⁵¹Cr-labeled target cells (2 × 10⁴) were then added in a volume of 0.1 ml to give a final volume of 0.2 ml and an effector (E)-to-target (T) cell ratio ranging from 100:1 to 12.5:1. The plates were then centrifuged at 80g for 5 min and incubated at 37°C for 4 h in a 5% CO₂ humidified atmosphere. After incubation, the plates were centrifuged at 250g for 10 min, and 0.1 ml of supernatant was harvested from each well and counted in a gamma-scintillation counter (Cobra II Monodetector, model 5003, Packard Instrument Co.).

Evaluation of Cytotoxic Activity of Effector Cells. The percentage of specific target cell lysis was calculated as follows:

\[
\text{Specific lysis (\%)} = \frac{\text{Test cpm} - \text{autologous cpm}}{\text{Total cpm} \times 0.5} \times 100
\]

where test cpm is the mean cpm relative to ⁵¹Cr released in presence of effector cells, autologous cpm is the mean cpm relative to ⁵¹Cr released by target cells incubated with unlabeled autologous cells in place of effector cells, and total cpm is the mean cpm of 2 × 10⁴ ⁵¹Cr-labeled target cells (i.e., total radioactivity incorporated by target cells).

To express cytolytic effects using a single value instead of a concentration-effect curve, cytotoxic activity of effector cells was expressed in terms of the number of target cells lysed (i.e., "sacrificed") by a fixed number of effector cells, calculated as follows:

\[
KC(m) = \frac{m \times T \times n\%}{E \times n + 100}
\]

where \(KC(m)\) is the number of target cells sacrificed by \(m\) effector cells, \(T\) is the total number of target cells present in each well, \(E\) is the number of effector cells present in each well at the selected E/T cell ratio, and \(n\%\) is the specific lysis produced theoretically by \(E\) effector cells. The \(n\%\) value is extrapolated from the best-fit curve obtained by plotting the different percentages of specific lysis against the logarithm of the number of effector cells/well. In the present study, \(KC(m)\) was calculated for \(m = 1 \times 10^6\) cells (i.e., \(KC(10^6)\)), and \(E = 2 \times 10^6\) cells (i.e., at an E/T cell ratio of 100:1).

Cytotoxic activity of LAK cells and CTL was also expressed in terms of \(KC\) (culture) (i.e., the number of target cells potentially lysed by the total number of effector cells present in each culture at the end of stimulation period (calculated multiplying \(KC(10^6)\) values by the total number of effector cells recovered from each culture). This parameter was introduced to illustrate the effect of TMZ on activation and expansion of cytotoxic effector cells using a single value.

Evaluation of MNC Sensitivity to TMZ. MNC sensitivity to TMZ was expressed in terms of 50% inhibitory drug concentration (IC₅₀, or the concentration of drug capable of inhibiting MNC proliferative responses or cytotoxic activity by 50%) calculated on the regression line in which cpm (for proliferative responses) or \(KC(10^6)\) or \(KC\) (culture); for cytotoxic activity) values were plotted against the logarithm of drug concentration.

In selected cases, IC₅₀ data were accompanied by the respective confidential intervals calculated on the bases of a p value of .05.

OGAT Assay. MNCs, either untreated or exposed to BG, were washed twice with PBS and stored as pellets at −80°C until used. OGAT activity was determined by measuring the transfer of ³²H-methyl groups from a DNA substrate to the OGAT protein (Morten and Margison, 1988). Briefly, cells pellets were thawed, resuspended in 1 ml of lysis buffer (0.5% 3-[(3-cholamidopropyl)dimethylammonio]propanesulfonate, 50 mM Tris·HCl pH 8.0, 1 mM EDTA, 3 mM dithiothreitol, 100 mM NaCl, 10% glycerol, 2 mg/ml leupeptin), and incubated for 30 min at 4°C. Cell lysates were then centrifuged at 15,000 rpm for 10 min. Aliquots of supernatants were then diluted in 50 mM Tris·HCl buffer, pH 8.3, containing 1 mM EDTA and 3 mM dithiothreitol and incubated with 10 μg of ³²H-methylated DNA at 37°C for 1 h. DNA was then hydrolyzed by heating samples at 75°C for 45 min in the presence of 1 N perchloric acid and protein precipitated with 1 mg of BSA as carrier. Pellets were washed with 1 N perchloric acid and resuspended in 0.01 N NaOH, and radioactivity counted in a liquid scintillation counter (TRI-CARB 1900) after the addition of scintillation liquid (Ultima Gold; Packard Instruments, Groningen, the Netherlands). Protein concentration in supernatants was evaluated according to the method of Bradford (1976) using the Bio-Rad (Heracles, CA) Dye Solution and BSA as standard. OGAT activity was expressed in terms of fmol ³²H-methyl groups transferred/mg of protein in cell extract.

Statistical Analysis. Differences in proliferative responses of control or drug-treated MNCs were evaluated using the use of the Student’s t test. Differences in cytotoxic activity of control or drug-treated MNCs were evaluated taking into account the percentage of specific cytotoxicity at all E/T ratios; therefore, p values were calculated using ANCOVA performed on the regression of the percentage of specific ⁵¹Cr release over the logarithm of the number of effector cells/well. All the data relative to cell-mediated cytolyis were expressed in terms of \(KC(10^6)\) or \(KC\) (culture) values, without conventional S.E. or S.D. values. Actually, no statistical analysis can be performed using these parameters, which are not suitable for ANCOVA of regression lines.

Results

OGAT Activity of MNCs Obtained from Peripheral Blood of Healthy Donors. The level of OGAT activity was evaluated in MNCs obtained from 22 different healthy donors. The results (Fig. 1) show that a wide range of enzyme activity (370–1500 fmol/mg protein) was detectable in MNCs. However, the majority of the samples showed OGAT levels ranging from 800 to 1100 fmol/mg protein; only 3 of 22 samples showed enzyme activity lower than 500 fmol/mg protein. These MNCs were considered to be endowed with low OGAT levels.

Relationship between OGAT Activity of MNCs and TMZ-Mediated Impairment of Proliferative Responses Induced by IL-2 or by Allosensitization with MT-2 Cells. The effects of TMZ on MNC proliferative responses induced by IL-2 or inactivated allogeneic MT-2 tumor cells were evaluated in samples endowed with different OGAT levels. The relationship between OGAT activity and MNC sensitivity to TMZ is illustrated in Fig. 2. The results show that TMZ inhibited MNC proliferation elicited by IL-2 (Fig. 2A) or by allostimulation (Fig. 2B) to comparable extents, with IC₅₀ values ranging between 134 and 515 μM. In both cases, MNC sensitivity to the drug was inversely correlated with OGAT activity.
Relationship between OGAT Activity of MNCs and TMZ-Induced Impairment of NK Function and of LAK Cell and CTL Generation. The effect of TMZ on NK function was evaluated in three MNC samples endowed with markedly different enzyme activity. The results illustrated in Table 1 shows that TMZ inhibited moderately the NK function, with the IC$_{50}$ of the agent being about 400 µM. However, these inhibitory effects were not clearly dependent on the level of OGAT activity, being similar for all the three MNC preparations used.

The effects of TMZ on LAK cell or CTL generation were evaluated in five MNC samples expressing different OGAT activity. For each sample, IC$_{50}$ values were calculated on the regression lines obtained by plotting either KC(10$^6$) or KC(culture) values against the logarithm of drug concentration. Correlation coefficients were 0.92 and 0.98 for A and B, respectively.

### Table 1

<table>
<thead>
<tr>
<th>Donor</th>
<th>OGAT Activity$^b$</th>
<th>TMZ IC$_{50}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>445 ± 19</td>
<td>361 (285–455)</td>
</tr>
<tr>
<td>10</td>
<td>792 ± 26</td>
<td>362 (316–413)</td>
</tr>
<tr>
<td>9</td>
<td>1400 ± 46</td>
<td>408 (309–539)</td>
</tr>
</tbody>
</table>

$^a$ MNC, obtained from the indicated donors, were exposed to graded concentration of TMZ (62.5–500 µM) for 4 h, washed, and tested for cytotoxic activity against K562 target cells, using a $^{51}$Cr-release assay (see Materials and Methods).

$^b$ OGAT activity is expressed in terms of fmol of $^3$H-methyl groups transferred per mg of protein in cell extract. Each value represents the arithmetic mean ± S.E. of at least three independent experiments.

$^c$ MNC sensitivity to TMZ is expressed in terms of IC$_{50}$, i.e., the concentration of drug capable of inhibiting MNC cytotoxic activity by 50%, calculated on the regression line in which KC(10$^6$) values were plotted against the logarithm of drug concentration. In parentheses, confidential limits of IC$_{50}$.
that the values of \( KC \) was observed when IC\(_{50} \) values were calculated with \( KC(\text{culture}) \) were lower than those calculated with \( KC(10^6) \). This finding can be explained taking into account that the values of \( KC(\text{culture}) \) result from the drug-induced impairment of both proliferation and lytic activity induction of MNCs. Comparable inhibition of LAK cell and CTL generation impairment of both proliferation and lytic activity induction of MNCs. Comparable inhibition of LAK cell and CTL generation was observed when IC\(_{50} \) values were calculated using \( KC(10^6) \). On the other hand, TMZ appeared to be slightly more effective in reducing CTL than LAK cell generation when IC\(_{50} \) was calculated with \( KC(\text{culture}) \).

**Influence of BG on TMZ-Induced Impairment of Cell-Mediated Immune Responses of MNCs.** To further confirm the relationship between OGAT activity and MNC sensitivity to TMZ, the influence of BG on TMZ-mediated impairment of immune responses induced by IL-2 or by allogeneic MT-2 cells was investigated. Studies were performed to establish whether exposure to BG before and during TMZ treatment was sufficient to increase MNC sensitivity to the triazene compound. It was also tested whether additional exposure to the OGAT inhibitor after TMZ treatment (i.e., during the stimulation period with IL-2 or MT-2 cells) was required for amplification of the suppressive effects of the triazene compound on MNC function.

The results of Fig. 4 refer to a representative experiment performed with MNCs obtained from donor 21, endowed with OGAT activity of 903 ± 77 fmol/mg protein (i.e., belonging to the most representative class of OGAT values). Cell suspension was treated with TMZ or TMZ plus BG and then tested for proliferative responses after stimulation with IL-2 (Fig. 4A) or with allogeneic MT-2 cells (Fig. 4B). Stimulation of MNCs exposed to BG or TMZ plus BG was performed either in CM or in CM containing 2 \( \mu \)M BG. The results show that: 1) significant impairment of proliferative responses of MNCs treated with TMZ alone occurred only at concentrations of 250 and 500 \( \mu \)M; 2) exposure to BG before, during, and after treatment with TMZ (i.e., “continuous exposure” to BG) substantially reduced the IC\(_{50} \) value of the triazene compound (see legend for Fig. 4); 3) continuous exposure to BG alone did not affect MNC proliferative responses and 4) no amplification of the suppressive effect of TMZ was obtained if MNCs pretreated with TMZ plus BG were stimulated without the OGAT inhibitor (see legend for Fig. 4).

The influence of BG on TMZ-mediated immunotoxicity was also investigated in terms of cell-mediated cytolytic effects (Fig. 5), using the same MNCs tested for cell proliferation (i.e., MNCs of donor 21). The results of the experiments performed, according to the same treatment schedules described for Fig. 4, show comparable results for LAK cells (Fig. 5A) and CTL function (Fig. 5B). Actually, the inhibitory effects of TMZ on cytotoxic activity were only amplified by the continuous exposure of MNCs to BG, as demonstrated by IC\(_{50} \) values (see legend for Fig. 5).

An evaluation of OGAT activity of MNCs showed that 1-h exposure to BG reduced the enzyme activity to undetectable levels (data not shown). However, complete OGAT recovery occurred within 72 h after BG removal (data not shown). On the other hand, continuous exposure to BG ensured persistent depletion of the enzyme activity (data not shown).

Additional experiments were performed with MNCs obtained from donor 19 (OGAT activity, 375 ± 30 fmol/mg protein), representative of the “low OGAT activity” class. The cells were treated with TMZ or TMZ plus BG and then sensitized with allogeneic MT-2 cells. MNCs pretreated with BG or TMZ plus BG were sensitized either in CM alone or in CM containing 2 \( \mu \)M. MNCs proliferation was evaluated by the \( ^{3} \text{H}-\text{Tdr} \) incorporation assay and expressed in terms of mean cpm calculated on four replicates. Bars, S.E. The IC\(_{50} \) values and their confidential limits for TMZ relative to MNCs proliferative response to IL-2 (A) were TMZ alone, 216 (196–237) and TMZ plus BG, 149 (118–180). The IC\(_{50} \) values and their confidential limits for TMZ relative to MNCs proliferative responses to allogeneic MT-2 cells (B) were TMZ alone, 201 (175–232) and TMZ plus BG, 98 (72–134). Because no overlapping occurred between confidential limits relative to IC\(_{50} \), all cases differences between IC\(_{50} \) values relative to TMZ and IC\(_{50} \) values relative to TMZ plus BG were statistically significant (p < .05). When stimulation of MNCs pretreated with TMZ plus BG was performed without the OGAT inhibitor, no increment was observed in the suppressive effect of the triazene compound (data not shown).

**Fig. 4.** Influence of BG on TMZ-mediated impairment of proliferative responses of MNCs endowed with high OGAT activity. MNCs obtained from donor 21 (OGAT activity, 903 ± 77 fmol/mg protein) were incubated in CM alone or in CM containing BG (2 \( \mu \)M) for 1 h. Control and BG-treated MNCs were then exposed to CM alone or to CM containing 250 \( \mu \)M TMZ, 125 \( \mu \)M TMZ, 250 \( \mu \)M TMZ, or 500 \( \mu \)M TMZ, without removing the OGAT inhibitor, for 4 h. Thereafter, cells were washed and tested for their ability to proliferate in response to IL-2 (A) or allogeneic MT-2 cells (B). Stimulation of MNCs pretreated with BG or TMZ plus BG was performed either in CM alone or in CM containing 2 \( \mu \)M BG. MNCs proliferation was evaluated by the \( ^{3} \text{H}-\text{Tdr} \) incorporation assay and expressed in terms of mean cpm calculated on four replicates. Bars, S.E. The IC\(_{50} \) values and their confidential limits for TMZ relative to MNCs proliferative response to IL-2 (A) were TMZ alone, 216 (196–237) and TMZ plus BG, 149 (118–180). The IC\(_{50} \) values and their confidential limits for TMZ relative to MNCs proliferative responses to allogeneic MT-2 cells (B) were TMZ alone, 201 (175–232) and TMZ plus BG, 98 (72–134). Because no overlapping occurred between confidential limits relative to IC\(_{50} \), all cases differences between IC\(_{50} \) values relative to TMZ and IC\(_{50} \) values relative to TMZ plus BG were statistically significant (p < .05). When stimulation of MNCs pretreated with TMZ plus BG was performed without the OGAT inhibitor, no increment was observed in the suppressive effect of the triazene compound (data not shown).

**Effect of Multiple TMZ Treatments on Cell-Mediated Immune Function of MNCs.** Pharmacokinetics studies have
shown that patients receiving TMZ on a repeated dose schedule (200 mg/m² × 5 days) attain a maximum plasma concentration of about 50 µM after each TMZ administration (Newlands et al., 1992). We therefore decided to verify whether an in vitro TMZ treatment of MNCs resembling the clinical condition could determine an impairment in cell-mediated immunity.

To this end, MNCs obtained from donor 21 were incubated with the triazene compound was observed (data not shown).

of LAK cells or CTL. The effect of BG on MNC sensitivity to TMZ was also evaluated.

The results illustrated in Fig. 7A show that the MNC ability to proliferate in response to IL-2 or MT-2 cells was reduced by TMZ of about 35 to 40%. Moreover, BG treatment resulted in a further and significant (p < .01) increase in TMZ-induced inhibition of proliferative responses. The multiple TMZ treatment also impaired MNC ability to generate

Fig. 5. Influence of BG on TMZ-mediated impairment of LAK cell and CTL generation of MNCs endowed with high OGAT activity. MNCs obtained from donor 21 were incubated in CM alone or in CM containing BG (2 µM) for 1 h. Control and BG-treated MNCs were then exposed to CM alone (■) or to CM containing 62.5 µM TMZ (□), 125 µM TMZ (■), 250 µM TMZ (□), or 500 µM TMZ (■), without removing the OGAT inhibitor, for 4 h. Thereafter, cells were washed and incubated in the presence of IL-2 (500 IU/ml) for 4 days (A) or in the presence of allogeneic inactivated MT-2 cells for 5 days (B). Stimulation of MNCs pretreated with BG or TMZ plus BG was performed either in CM alone or in CM containing 2 µM BG. At the end of incubation period, effector cells were recovered and tested for cytotoxic activity against Daudi cells (LAK cells; A) or MT-2 cells (CTL; B), using a 5¹Cr-release assay (see Materials and Methods). Cytotoxic activity (y-axis) is expressed in terms of KC/culture (i.e., the number of target cells sacrificed by the total number of effector cells present in each culture at the end of stimulation period, see Materials and Methods), calculated on four replicates. The IC₅₀ values and their confidential limits for TMZ relative to LAK cell cytotoxic activity (A) were TMZ alone, 252 (232–278) and TMZ plus BG, 144 (118–180). The IC₅₀ values and their confidential limits for TMZ relative to CTL cytotoxic activity (B) were TMZ alone, 221 (154–319) and TMZ plus BG, 82 (98–62). Because no overlapping occurred between confidential limits relative to IC₅₀ in all cases, differences between IC₅₀ values relative to TMZ and IC₅₀ values relative to TMZ plus BG were statistically significant (p < .05). When stimulation of MNCs pretreated with TMZ plus BG was performed without the OGAT inhibitor, no increment in the suppressive effect of the triazene compound was observed (data not shown).

Fig. 6. Influence of BG on TMZ-mediated impairment of cell-mediated immune responses to allogeneic MT-2 of MNCs endowed with low OGAT activity. MNCs obtained from donor 19 (OGAT activity, 375 ± 30 fmol/mg protein) were incubated in CM alone or in CM containing BG (2 µM) for 1 h. Control and BG-treated MNCs were then exposed to CM alone (■) or to CM containing 62.5 µM TMZ (□), 125 µM TMZ (■), 250 µM TMZ (□), or 500 µM TMZ (■), without removing the OGAT inhibitor, for 4 h. Thereafter, cells were washed and incubated in the presence of inactivated allogeneic MT-2 cells for 5 days to test their ability to proliferate (A) and to generate CTL (B). Stimulation of MNCs pretreated with BG or TMZ plus BG was performed either in CM alone or in CM containing 2 µM BG. A, at the end of the incubation period, MNC proliferation was evaluated by the 3H-TdR incorporation assay and expressed in terms of mean cpm calculated on four replicates. Bars, S.E. Statistical analysis of the differences between groups treated with TMZ alone or with TMZ plus BG was performed with Student's t-test. *p < .05, **p < .01. The IC₅₀ values and their confidential limits for TMZ relative to MNC proliferative responses to allostimulation were TMZ alone, 154 (124–190) and TMZ plus BG, 87 (57–129). B, the cytotoxic activity of CTL was tested against MT-2 cells using a 5¹Cr-release assay (see Materials and Methods) and expressed in terms of KC/culture (culture) (see legend for Fig. 5) calculated on four replicates. Statistical analysis of the differences between groups treated with TMZ alone or with TMZ plus BG was performed by ANCOVA. ***p < .01. The IC₅₀ values and their confidential limits for TMZ relative to CTL cytotoxic activity were TMZ alone, 118 (98–144) and TMZ plus BG, 77 (51–129). When stimulation of MNCs pretreated with TMZ plus BG was performed without the OGAT inhibitor, no increment in the suppressive effect of the triazene compound was observed (data not shown).
The 5-day TMZ treatment of MNCs preexposed to BG was performed in CM containing 2 μM BG for 1 h. Then, either untreated or BG-treated MNCs were exposed daily to 50 μM TMZ for 5 days. The 5-day TMZ treatment of MNCs preexposed to BG was performed in CM containing 2 μM BG. Four hours after the last TMZ treatment, MNCs were tested for their ability to respond to IL-2 and allogeneic MT-2 tumor cells in terms of proliferation (A) or generation of cytotoxic effector cells (B). A, MNC proliferation was evaluated by the 3H-ThdR-incorporation assay and expressed in terms of mean cpm calculated on four replicates. Bars, S.E. Statistical analysis of the differences between groups treated with TMZ alone or with TMZ plus BG (data not shown). This finding is in agreement with the observation that the IC50 values relative to TMZ calculated on KC(culture) were lower than those calculated on KC(106), suggests that inhibition of LAK cell and CTL generation is largely dependent on the antiproliferative effects of TMZ. This hypothesis is also supported by the observation that NK cell activity, which does not involve MNC expansion, was only moderately affected by TMZ, with no obvious relationship with OGAT function (Table 1). In addition, TMZ-mediated impairment of NK activity was not influenced by MNC preexposure to BG (data not shown).

The involvement of O6-G methylation in the immunosuppressive effects of TMZ is further confirmed by the finding that continuous exposure to BG increased the sensitivity to TMZ of MNCs endowed with high OGAT levels. It must be emphasized that continuous exposure to BG ensured persistent abrogation of OGAT activity of MNCs, as extensively described in Results. Both proliferative responses and generation of cytotoxic effectors induced by IL-2 or allogeneic tumor cells were impaired to a higher extent in MNCs treated with TMZ plus BG with respect to MNCs treated with TMZ alone (Figs. 4 and 5). In MNCs possessing low OGAT levels, the effect of BG on sensitivity to TMZ was limited, and the decrease in the IC50 values, although present, did not reach statistical significance (Fig. 6). However, if the influence of BG was analyzed on the basis of each single TMZ concentration, a potentiating effect of the inhibitor could be demonstrated at the lowest drug concentrations (i.e., 62.5 and 125 μM). On the other hand, when 250 or 500 μM of TMZ was used, the drug alone was highly effective in abrogating immune responses, and therefore exposure of MNCs to BG did not result in a further increase in immunosuppression. Similar patterns of differential effects of BG on the susceptibility to triazenes and other O6-G alkylating agents have been found in human tumor cells (Dolan et al., 1991; Baer et al., 1993; Wedge et al., 1996a).

Presently, the treatment schedule recommended for TMZ is 200 mg/m2 × 5 days. Pharmacokinetics studies have
shown that patients receiving TMZ with this schedule attain
a maximum plasma concentration of about 50 μM after each
TMZ administration (Newlands et al., 1992). The results of
Figs. 4, 5, and 6 show that a single treatment with 62.5 μM
TMZ (concentration comparable to that obtainable in the
clinic) did not impair the immune functions of MNCs en-
dowed with either high or low OGAT activity. However, when
MNCs with high enzyme levels were exposed to five subse-
quent treatments with 50 μM TMZ, a significant inhibition
was observed of both proliferative response and cytotoxic
effector generation induced by IL-2 or allogeneic tumor cells (Fig. 7). Also in this case, the combined treatment of TMZ
plus BG was more effective than TMZ alone in inhibiting
MNC immune functions.

Taken together, these data demonstrate that TMZ down-
regulates both natural and antigen-dependent cell-mediated
immune functions in vitro and suggest that this could also occur
in patients with cancer treated with the agent. Indeed, it has
already been shown that in patients with melanoma receiving
TMZ (150 mg/m²) on a 5-day schedule, a significant and
progressive depletion of OGAT activity occurred in MNCs (Lee et
al., 1994). If a complete loss of OGAT activity occurs in MNCs,
an excess of the toxic O6-MeG lesions and, hence, immunode-
pression might be expected to take place. Complete suppression
of OGAT activity of MNCs might occur preferentially in MNCs
endoled with low levels of the protein, as already described in
patients with melanoma treated with the methylating triazene
compound CB10-277 (Sio et al., 1992).

On the basis of the results obtained in vitro, it is reason-
able to predict that the NK function should not be substanc-
tially depressed by TMZ shortly after treatment in vivo. On the
contrary, the ability of MNCs to generate LAK cells and
antigen-dependent CTL is expected to be reduced in patients
undergoing TMZ treatment. Therefore, the determination of
individual OGAT levels in normal lymphocytes could provide
valuable information into the susceptibility of the host to
TMZ-induced impairment of the immune system.

The use of BG to potentiate the antitumor effects of TMZ
could also result in a further increase of TMZ-induced immu-
nodepression. However, a continuous exposure of MNCs to the
inhibitor is required to enhance the immunotoxicity of TMZ.
These findings should be taken into consideration in the
designing the protocols of immunotherapy. Actually, treatment
with triazenes combined with BG could interfere with the
immunosstimulating activity of cytokines such as IL-2 or active
immunization of patients against tumor-associated antigen.

Acknowledgements

We thank Augusto Mari and Cesare Secci for the excellent art-
work. We also thank Mauro Scarpellini and Dr. Federica Pochesci
for secretarial assistance.

References

Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA and Margison GP
(1993) Depletion of O6-alkylguanine-DNA alkyltransferase correlates with poten-
tialization of temozolomide and CCNU toxicity in human tumor cells. Br J Cancer
67:1299–1302.

Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH, Rustin GJ,
Brampton M and Stevens MP (1995) Cancer Research Campaign Phase II trial of

Bonmassar E, D’Atri S, Turriziani M and Giuliani A (1994) In vitro combined effects
of triazene compound and interferon-beta on natural immunity against lympho-
blastoid cell lines: Studies at effector and target cell level. Immunopharm Immunot
16:955–715.

Bower M, Newlands ES, Bleehen NM, Bradu M, Begent RJ, Calvert H, Colquhoun I,
Lewis P and Brampton MH (1997) Multicentre CRC phase II trial of temozolomide
in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol
40:484–488.

Bradford MM (1976) A rapid and sensitive method for quantitation of microgram
quantities of protein utilizing the principle of protein dye binding. Anal Biochem

Carethers JM, Hawin MT, Chauhan DP, Luce MC, Marra G, Koi M and Boland CR

Citron M, Decker R, Chen S, Schneider S, Graver M, Kleynerman L, Kahn LB, White
in human normal and tumor tissue from brain, lung and ovary. Cancer Res
51:4131–4134.

Cohen GL and Falkson CI (1998) Current treatment options for malignant mela-

D’Atri S, Piccioni D, Castellano A, Tuoro V, Franchi A, Lu K, Christiansen N,
triarene compounds and O6-alkylguanine-DNA alkyltransferase levels: Studies with

D’Atri S, Tenenti L, Lical PM, Graziani C, Pagani E, Benincasa E, Zambruno G,
Bonmassar E and Jiricny J (1998) Involvement of the mismatch repair system in

enzyme O6-alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev
16:279–292.

O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic

alkyltransferase activity by O6-benzylguanine is a method to evaluate the role
of this protein in protection against carcinogenic and therapeutic alkylating


of the O6-alkylguanine-DNA-methyltransferase gene MGMT in MER and

O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat

Giampietri A and Bonmassar E (1978) Drug-induced modulation of immune re-

temozolomide in human peripheral blood mononuclear cells by temozolomide.
Br J Cancer 71:143–150.

of triarene compound and interferon-beta on natural immunity against lympho-
blastoid cell lines: Studies at effector and target cell level. Immunopharm Immunot
16:955–715.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.

Hata H, Kogure K and Kiyosue Y (1995) Inhibition of cell growth by O-(2-
alkyl-1H-imidazol-4-yl)alkylguanine derivatives. Mol Pharmacol 47:790–798.
Triazene compounds induce apoptosis in O\textsuperscript{6}-alkylguanine-DNA alkyltransferase deficient leukemia cell lines. *Leukemia (Baltimore)* 9:1888–1895.


Send reprint requests to: Dr. Stefania D’Atri, Istituto Dermopatico Dell’Immacolata (IDI-IRCCS), Via dei Monti di Creta 104, 00167 Rome, Italy. E-mail: s.datri@idi.it